Role of Endothelin-1 in human aneurysmal subarachnoid hemorrhage: Associations with vasospasm and delayed cerebral ischemia

Neurocritical Care

Volumn 15, Issue 1, 2011, Pages 19-27

  Thampatty, Bhavani P ^a   Sherwood, Paula R ^a   Gallek, Matthew J ^c   Crago, Elizabeth A ^a   Ren, Dianxu ^a   Hricik, Allison J ^b   Kuo, Chien Wen J ^a   Klamerus, Megan M ^e   Alexander, Sheila A ^a   Bender, Catherine M ^a   Hoffman, Leslie A ^a   Horowitz, Michael B ^b   Kassam, Amin B ^d   Poloyac, Samuel M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Department of Neurosurgery   (United States)

^e EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

ASAH; CSF; DCI; Endothelin 1; Vasospasm

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ISCHEMIA; BRAIN VASOSPASM; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DELAYED CEREBRAL ISCHEMIA; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; ILLNESS TRAJECTORY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUBARACHNOID HEMORRHAGE;

ADULT; AGED; BRAIN ISCHEMIA; COHORT STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SOCIOECONOMIC FACTORS; SUBARACHNOID HEMORRHAGE; TIME FACTORS; VASOSPASM, INTRACRANIAL;

EID: 80052611964     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9508-9     Document Type: Article

References (41)

1. Saveland H, Sonesson B, Ljunggren B, et al. Outcome evaluation following subarachnoid hemorrhage. J Neurosurg. 1986;64: 191-6. (Pubitemid 16140330)
2. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: A systematic review. Stroke. 1997;28:660-4. (Pubitemid 27118394)
3. Haug T, Sorteberg A, Sorteberg W, Lindegaard KF, Lundar T, Finset A. Cognitive outcome after aneurysmal subarachnoid hemorrhage: Time course of recovery and relationship to clinical, radiological, and management parameters. Neurosurgery. 2007;60: 649-56. discussion 656-7. (Pubitemid 46581085)
4. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke. 2000;31:2971-5.
5. Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol. 2000;53:131-5. (Pubitemid 30122318)
6. Kastner S, Oertel MF, Scharbrodt W, Krause M, Boker DK, Deinsberger W. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien). 2005;147:1271-9. discussion 1279. (Pubitemid 41674372)
7. Kessler IM, Pacheco YG, Lozzi SP, de Araujo Jr AS, Onishi FJ, de Mello PA. Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2005;64(Suppl 1):S1:2-5. discussion S1:5.
8. Suzuki H, Sato S, Suzuki Y, Takekoshi K, Ishihara N, Shimoda S. Increased endothelin concentration in CSF from patients with subarachnoid hemorrhage. Acta Neurol Scand. 1990;81:553-4. (Pubitemid 20220567)
9. Ehrenreich H, Lange M, Near KA, et al. Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med (Berl). 1992;192:257-68.
10. Gaetani P, Rodriguez y Baena R, Grignani G, Spanu G, Pacchiarini L, Paoletti P. Endothelin and aneurysmal subarachnoid haemorrhage: A study of subarachnoid cisternal cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 1994;57:66-72. (Pubitemid 24030910)
11. Pluta RM, Boock RJ, Afshar JK, et al. Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 1997;87:287-93. (Pubitemid 27349116)
12. Sloan MA, Haley EC Jr, Kassell NF, et al. Sensitivity and specificity of transcranial Doppler ultrasonography in the diagnosis of vasospasm following subarachnoid hemorrhage. Neurology. 1989; 39:1514-8. (Pubitemid 19286013)
13. Spilker J, Kongable G, Barch C, et al. Using the NIH Stroke Scale to assess stroke patients. The NINDS rt-PA Stroke Study Group. J Neurosci Nurs. 1997;29:384-92.
14. Nagin D. Analyzing developmental trajectories: A semi-parametric, group-based approach. Psychol Methods. 1999;4:139-57.
15. Jones BL, Nagin DS, Roeder KA. SAS procedure based on mixture models for estimating developmental trajectories. Sociological Methods and Research. 2001;29:374-93.
16. Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16: 562-72. (Pubitemid 15007226)
17. Yamaura I, Tani E, Maeda Y, Minami N, Shindo H. Endothelin-1 of canine basilar artery in vasospasm. J Neurosurg. 1992;76: 99-105.
18. Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg. 1995;82:55-62.
19. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 1992;77:96-100.
20. Mascia L, Fedorko L, Stewart DJ, et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2001; 32:1185-90.
21. Maier B, Lehnert M, Laurer HL, Marzi I. Biphasic elevation in cerebrospinal fluid and plasma concentrations of endothelin 1 after traumatic brain injury in human patients. Shock. 2007;27: 610-4. (Pubitemid 46788159)
22. Nagin D, Tremblay RE. Trajectories of boys' physical aggression, opposition, and hyperactivity on the path to physically violent and nonviolent juvenile delinquency. Child Dev. 1999;70: 1181-96.
23. Herrenkohl TI, Hill KG, Hawkins JD, Chung IJ, Nagin DS. Developmental trajectories of family management and risk for violent behavior in adolescence. J Adolesc Health. 2006;39: 206-13. (Pubitemid 44062343)
24. Broadbent JM, Thomson WM, Poulton R. Trajectory patterns of dental caries experience in the permanent dentition to the fourth decade of life. J Dent Res. 2008;87:69-72.
25. Hu MC, Muthen B, Schaffran C, Griesler PC, Kandel DB. Developmental trajectories of criteria of nicotine dependence in adolescence. Drug Alcohol Depend. 2008;98:94-104.
26. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109-38.
27. Clozel M, Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci. 1993;52:825-34.
28. Itoh S, Sasaki T, Asai A, Kuchino Y. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: Change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg. 1994;81:759-64. (Pubitemid 24328704)
29. Shigeno T, Clozel M, Sakai S, Saito A, Goto K. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery. 1995;37: 87-90. discussion 90-1.
30. Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhageinduced cerebral vasospasm. Stroke. 1998;29:1924-9. (Pubitemid 28399991)
31. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV- 034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005; 103:9-17. (Pubitemid 43193928)
32. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double- blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015-21.
33. Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis. Stroke. 2009;40: 3403-6.
34. Armstead WM. Endothelin-1 contributes to normocapnic hyperoxic pial artery vasoconstriction. Brain Res. 1999;842:252-5. (Pubitemid 29447878)
35. Armstead WM. Age-dependent impairment of K(ATP) channel function following brain injury. J Neurotrauma. 1999;16: 391-402. (Pubitemid 29264791)
36. Armstead WM. ET-1 contributes to age-dependent G protein impairment after brain injury. J Neurotrauma. 2003;20:105-10. (Pubitemid 36176964)
37. Ohkuma H, Manabe H, Tanaka M, Suzuki S. Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2000;31:1621-7. (Pubitemid 30437513)
38. Dreier JP, Woitzik J, Fabricius M, et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain. 2006;129: 3224-37. (Pubitemid 44871438)
39. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB. Microthrombosis after aneurysmal subarachnoid hemorrhage: An additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab. 2008;28:1761-70.
40. Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: A model for an endothelial trigger of migrainous aura? Brain. 2002; 125:102-12.
41. Meyer-Lehnert H, Wanning C, Predel HG, Backer A, Stelkens H, Kramer HJ. Effects of endothelin on sodium transport mechanisms: Potential role in cellular Ca2+ mobilization. Biochem Biophys Res Commun. 1989;163:458-65. (Pubitemid 19227327)